SRT-2183

SRT-2183
Clinical data
ATC code	None;
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name N-[2-(3-{[(3R)-3-hydroxypyrrolidin-1-yl]methyl}imidazo[2,1-b][1,3]thiazol-6-yl)phenyl]naphthalene-2-carboxamide;
CAS Number	1001908-89-9 ;
PubChem CID	24180126;
ChemSpider	23315224 ;
UNII	6FKU9G9CX6;
ChEMBL	ChEMBL403308 ;
CompTox Dashboard (EPA)	DTXSID501029656 ;
Chemical and physical data
Formula	C27H24N4O2S
Molar mass	468.58 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c1ccc2cc(ccc2c1)C(=O)Nc3ccccc3c4cn5c(csc5n4)CN6CC[C@H](C6)O;
	InChI InChI=1S/C27H24N4O2S/c32-22-11-12-30(15-22)14-21-17-34-27-29-25(16-31(21)27)23-7-3-4-8-24(23)28-26(33)20-10-9-18-5-1-2-6-19(18)13-20/h1-10,13,16-17,22,32H,11-12,14-15H2,(H,28,33)/t22-/m1/s1 ; Key:MUFSINOSQBMSLE-JOCHJYFZSA-N ;
	(verify)

SRT-2183 is a drug in development by Sirtris Pharmaceuticals intended as a small-molecule activator of the sirtuin subtype SIRT1. It has similar activity in animal studies to another SIRT1 activator SRT-1720, but is closer in potency to resveratrol. In animal studies it was found to improve insulin sensitivity and lower plasma glucose levels in fat, muscle and liver tissue, and increased mitochondrial and metabolic function.^[1] However, the claim that SRT-2183 is a SIRT1 activator has been questioned^[2] and further defended.^[3]